Al-Ola A Abdallah: Did the FDA Oncology make a big mistake by withdrawing Belantamab?

Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center, made the following post on X:

“It’s the BCMA Era for myeloma:

Cilta-Cel vs SOC (DPd/PVd): 12 months PFS 76% vs 49%
Ide-Cel vs SOC: mPFS 13.4 vs 4.4 months
Belantamab/Vd vs DVd: mPFS 37 vs 13.4 months
Did the FDA Oncology make a big mistake by withdrawing Belantamab?”

Source: Al-Ola A Abdallah/X